The Desmoid Tumor Research Foundation successfully lobbied Pfizer to revive development of nirogacestat after it was shelved. This advocacy was critical to the drug's eventual FDA approval, demonstrating the power of patient groups in rare disease drug development.
A crucial step in managing desmoid tumors is screening for Familial Adenomatous Polyposis (FAP). Since 10-15% of these tumors are associated with this hereditary colorectal cancer syndrome, a colonoscopy is mandatory to rule it out and guide further genetic evaluation.
Because up to 20% of desmoid tumors regress on their own, the standard of care for patients with non-critical tumors is to "watch and wait" for 1-2 years. This approach avoids unnecessary treatment and allows physicians to observe the tumor's natural history.
Once the primary treatment, surgery for desmoid tumors has fallen out of favor. Even with successful operations, recurrence rates can be as high as 70% within months. This has prompted a major shift towards systemic therapies and observation as first-line management.
Gamma secretase inhibitors, a class of drugs initially developed for Alzheimer's disease and later failed in other solid tumors, were successfully repurposed for desmoid tumors. This was due to their specific activity on the Wnt/Notch signaling pathways that drive this rare disease.
In desmoid tumors, traditional RECIST criteria for tumor response are inadequate. Patients report significant improvements in pain and functional status even with minor tumor shrinkage that doesn't qualify as a partial response, making patient-reported outcomes a more meaningful endpoint.
The field of sarcoma treatment has seen rapid progress by shifting from "one-size-fits-all" clinical trials to studies focused on specific histological subtypes. This targeted approach led to nearly 10 FDA approvals since 2019, revolutionizing care for these rare cancers.
To avoid committing young patients to lifelong daily medication, oncologists treating desmoid tumors with oral agents will consider "treatment holidays." After achieving maximum response, they may pause therapy and restart only upon symptomatic progression, balancing efficacy with quality of life.
While CAR-T therapy is known in blood cancers, engineered T-cell receptor (TCR) therapies are finding their first major successes in solid tumors within the sarcoma community. Treatments targeting MAGE-A4 and NY-ESO-1 in specific sarcomas are demonstrating high efficacy and leading development in the field.